A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2016
At a glance
- Drugs Cenobamate (Primary) ; Antiepileptic drugs
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors SK Life Science
- 21 Sep 2016 Status changed from completed to active, no longer recruiting.
- 21 Apr 2016 Pooled analysis of seizure-free rates of 2 studies including this trial and another study (see CTP 700203047) were presented at the 68th Annual Meeting of the American Academy of Neurology.
- 24 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.